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BACKGROUND Paravalvular regurgitation (PVR) has been associated
with adverse outcomes. Balloon post-dilation is an effective strategy
to treat PVR in case of frame under-expansion. We evaluated the
impact of device sizing and aortic valve calciﬁcation distribution on
paravalvular regurgitation and the need for post-dilation after trans-
catheter aortic valve replacement (TAVR) with the self-expanding
CoreValve prosthesis (Medtronic Inc., Minneapolis, MN).
METHODS We conducted a multicenter study, which included 183
consecutive patients undergoing CoreValve implantation with pre-
procedural multidetector computed tomography (MDCT). Quantita-
tive assessment of aortic root dimensions and calcium volume for
leaﬂet and left ventricular outﬂow tract (LVOT) were retrospectively
performed with MDCT in a centralized core laboratory.
RESULTS Moderate or severe PVR was reported in 27 patients (14.8%),
and post-dilation was performed in 58 patients (31.7%). Multivariable
analysis found perimeter oversizing (odds ratio [OR] 0.90; 95% con-
ﬁdence interval [CI]: 0.83 – 0.98; p ¼ 0.01) and leaﬂet calcium volume
(per increase of 100 mm3, OR 1.18; 95% CI: 1.06 – 1.31; p ¼ 0.002) as
independent predictors of signiﬁcant PVR with cutoff values of 13.6%
and 583 mm3, respectively. In terms of the need for post-dilation,
LVOT calciﬁcation was identiﬁed as independent predictor (OR 2.23;
95% CI: 1.09 – 4.58; p ¼ 0.028) as well as perimeter oversizing (OR
0.93; 95% CI: 0.88 – 0.99; p ¼ 0.015) and leaﬂet calcium volume (per
increase of 100mm3, OR 1.17; 95% CI: 1.05 – 1.31; p ¼ 0.004).
Comparing to the manufacture’s recommendation for prosthesis
sizing, satisfying cutoff value of perimeter oversizing (13.6%) would
reduce incidence of signiﬁcant PVR (7.1% vs. 33.3%; p < 0.001) and the
need for post-dilation (21.6% vs. 46.7%; p ¼ 0.011).
Multivariate Predictors of Signiﬁcant Paravalvular RegurgitationParametersUnivariate
analysis
OR (95% CI) p valueMultivariate
analysis
OR (95% CI) p valueFemale 0.41 (0.17 - 0.99) 0.048Body mass index 0.88 (0.78 - 0.99) 0.04Annulus
perimeter1.11 (1.04 - 1.18) 0.001Perimeter
oversizing0.86 (0.80 -
0.93)< 0.001 0.90 (0.83 -
0.98)0.01Leaﬂet calcium
volume per
increase of
100 mm31.24 (1.12 - 1.36) < 0.001 1.18 (1.06 - 1.31) 0.002CI ¼ conﬁdence interval; OR ¼ odds ratio
CONCLUSIONS Perimeter oversizing and leaﬂet calciﬁcation pre-
dicted signiﬁcant PVR after self-expanding TAVR. To avoid signiﬁcant
PVR, optimal device sizing and adequate post-dilation should be in-
tegrated into treatment strategy.CATEGORIES STRUCTURAL: Valvular Disease: Aortic
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BACKGROUND Patients with severe aortic valve stenosis undergoing
transcatheter aortic valve implantation (TAVI) have elevated NT-
proBNP values. There seems to be a correlation between the increased
value of this protein with the severity of the valvular stenosis,
although its meaning after TAVI is not well established. We aim to
analyze its prognostic value in our TAVI population.
METHODS Single center study of 193 prospectively included TAVI
patients admitted to our Cath lab (VCROSS registry), during a period of
6 years (5 patients were excluded due to peri-procedural death). The
primary objective was to assess the impact of pre and post-procedural
NT-proBNP in the prediction of 1-year mortality.
RESULTS 188 patients with a mean age of 81 (þ-7.7) years, 55.3% fe-
male, median STS mortality score of 5.1%(IQR 3.5-7.1), 10.1% with
LVEF <35%, median pre-procedure NT-proBNP of 2405 (IQR 1230-
7790) and post NT-proBNP 2190 ng/l (IQR 806-5485). There wasn’t a
signiﬁcant early post-procedural reduction of NT-proBNP levels
(p¼0.220). At one year there were 23 deaths (12.2%). Patients with
LVEF <35% had higher rates of mortality (36.8% vs.9.5%, p¼0.001), as
did patients with liver failure (50.0% vs. 11.4%, p¼0.020). Mortality at
one year was also signiﬁcantly related to higher STS scores (6.7% (IQR
4.65-10.73) in patients who died vs 5.1%(IQR 3.6-7-17), p¼0.039). NT-
proBNP value that better discriminated one year mortality was
2520ng/l. Levels above this cutoff were related to a higher mortality
(21.5% vs. 3.9%, p¼0.001). Multivariate Cox regression model revealed
that post procedural NT-proBNP >2520ng/l is the only independent
predictor of mortality (HR 6.27, CI 95%, 1,801-21,866, p¼0.004).
CONCLUSIONS Post-procedural NT-proBNP is an independent pre-
dictor of 1-year mortality and stratiﬁes a population at higher risk of
death. Pre and post TAVI levels of NT-proBNP help in the selection
and management of these patients.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is
well-established treatment for failing bioprosthetic valves in patients
at high-risk for conventional heart surgery. Elderly patients with
degenerated bioprostheses and signiﬁcant comorbidities are a sub-
group in which TAVI represents a viable option. However, small bio-
prostheses with outer diameter of 19-21 mm are frequently used in
these patients, representing a challenge for currently available
transcatheter valves, with a potential risk of residual transvalvular
gradient or regurgitation due to inadequate leaﬂet coaptation. The
new Medtronic CoreValve Evolut R provides several reﬁnements to
improve anatomical ﬁt, annular sealing, and durability. Moreover, the
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allowing exact positioning that is crucial in failing bioprostheses. We
evaluate the acute outcome of degenerated small aortic bioprostheses
treatment with the 23 mm Medtronic CoreValve Evolut R.
METHODS From a total of 560 TAVI performed at our Institute, we
selected 5 consecutive symptomatic patients with degenerated small
aortic bioprostheses showing stenosis, regurgitation or combined
failure. Patients (80  5.5 years) had Logistic EuroSCORE of 29.1  15.8
and STS score of 7.64  6.2. Fast-track general anesthesia with TEE
monitoring was used in all patients. All TAVI were performed by
percutaneous transfemoral access using the 23 mm Medtronic Cor-
eValve Evolut R. After pre-closure with two ProGlide closure devices
(Abbott Vascular), the EnVeo R 14 Fr-equivalent delivery system was
introduced in the common femoral artery and precisely positioned
under ﬂuoroscopic guidance without pre-dilation inside the failed
prostheses. The CoreValve Evolut R was then deployed without
rapid ventricular pacing. Valve recapturing was performed in case of
unsatisfactory positioning with the aim of obtaining minimum pro-
trusion of the CoreValve Evolut R frame below the bioprosthesis
implantation ring.
RESULTS Degenerated stented bioprostheses were one 21-mm Sorin
Mitroﬂow, one 21-mm Carpentier Edwards, one 21-mm Carpentier
Edwards Perimount, and two 19-mm Sorin Mitroﬂow. At MSCT, mean
internal diameter was 17.7 mm. Baseline TTE parameters were: aortic
valve area 0.67  0.17 cm2, peak/mean aortic gradient 69.2  20.3/
44.8  13.4 mmHg; aortic regurgitation was severe in one patient and
moderate in two. After TAVI, aortic valve area increased to 1.34  0.28
cm2, peak/mean aortic gradient decreased to 42.2  12.9/23.8 
6.09 mmHg. Paravalvular leak was mild in three patients and mod-
erate in one. No intra-procedural/in-hospital death, myocardial
infarction, coronary obstruction, stroke and major vascular compli-
cations were observed.
CONCLUSIONS Valve-in-valve treatment of degenerated small aortic
bioprostheses with the CoreValve Evolut R is feasible and safe.
Despite a signiﬁcant increase in aortic area and trans-aortic gradient in
all patients, the mean echocardiographic gradient remained elevated.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for patients with severe
native valve aortic stenosis unsuitable for surgery. Its use in patients
with low-gradient, low output aortic stenosis has not been prospec-
tively studied.
METHODS The CoreValve US Expanded Use Study was a prospective,
non-randomized, single-arm study that evaluated the safety and
effectiveness of TAVR in complex subsets that included extreme risk
patients with low-gradient low output (LGLO) aortic stenosis. LGLO
was deﬁned as Group A: mean gradient < 40 mmHg and peak
velocity < 4 M/sec and resting LVEF  50%, or Group B: mean
gradient < 40 mmHg and peak velocity < 4 M/sec and resting LVEF <
50% who did not augment with dobutamine. These results were
compared with patients enrolled in the Extreme Risk cohort of the US
Pivotal Trial, Group C: mean gradient < 40 mmHg and peak velocity <
4 M/sec and resting LVEF < 50% by resting echo, but who augmented
with dobutamine, and Group D: mean gradient  40 mmHg or peak
velocity  4 M/sec. The primary endpoint was a composite of all-cause
mortality or major stroke rate at 12 months.
RESULTS 189 patients with attempted implant were enrolled between
December 2012 and September 2014 in the Expanded Use Study(Groups A and B). Patients were elderly (81.8  8.7 years), commonly
men (56.6%) and were severely symptomatic (New York Heart Asso-
ciation class III or IV, 89.4%). The STS PROM was 9.9  5.4%. Cor-
eValve diameters included 23 mm (0.5%) 26 mm (22.9%), 29 mm
(39.4%), and 31 mm (37.2%).Group A Group B Group C Group DKM rate (%) or
Mean ± SDN ¼ 136 N ¼ 50 N ¼ 66 N¼ 550Baseline mean
gradient
(mmHg)129.5  4.5 25.1 5.2* 28.8  5.3Ŧ 51.4  12.9ŧBaseline aortic
valve area,
(cm2)10.8  0.2 0.8  0.2 0.7 0.3 0.6  0.2ŧ1 Year all-cause
mortality or
major stroke26.5 27.6 43.9 27.3ŧ1 Year all-cause
mortality22.2 27.6 39.4 25.8ŧ1 Year major
stroke6.7 0.0 11.8Ŧ 4.5ŧN[44 N[16 N[30 N[3351 Year effective
oriﬁce area
(cm2)11.8  0.5 1.9  0.5 1.5  0.4Ŧ 1.7  0.51Site reported data for Groups A and B. Core lab data for Groups C and D. *P<0.05 A vs. B; ŦP<0.05 B vs. C;
ŧP<0.05 C vs. D
CONCLUSIONS The use of CoreValve TAV in LGLO aortic stenosis at
extreme risk for surgery was associated with a low 12-month mortality
rate, and a signiﬁcantly improved aortic valve area that was compa-
rable to the results seen in the Pivotal trial.
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BACKGROUND The combination of severe aortic stenosis (AS) with a
small aortic annulus (SAA) presents a unique challenge to effectively
treat either surgically or percutaneously. The 20mm SAPIEN XT (SXT)
transcatheter heart valve (THV) is currently the smallest of its kind
available for transcatheter aortic valve implantation (TAVI). We report
the initial clinical outcomes and performance of this small THV.
